Bezafibrate
As of the edition of 20 October 2026, Bezafibrate is a small molecule: marketed, first approved in 1981 (ES); acts on PPARA, PPARD and PPARG.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2022
- Kind
- Small molecule
- Brand name
- Eulitop
- First approved
- 1 December 1981 (ES)
- Approvals on record
- 4 in 4 regions
- Holder of the most recent approval
- TEVA FARMACĂUTICA LTDA.; 4 holders in all
- Registered trials
- 18, 1 stopped early
- Disease areas
- Digestive system; Nutrition and metabolism; Heart and blood vessels; Hormones; Blood and lymph; Inherited and neonatal
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 2 | 1 | 1 | 0 |
| Phase 2 | 7 | 5 | 0 | 1 |
| Phase 3 | 7 | 3 | 0 | 0 |
| Phase 4 | 2 | 2 | 0 | 0 |
| All trials | 18 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| AbbVie | Applicant | 1994 to now |